Central Nervous System Agents
"Central Nervous System Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of drugs producing both physiological and psychological effects through a variety of mechanisms. They can be divided into "specific" agents, e.g., affecting an identifiable molecular mechanism unique to target cells bearing receptors for that agent, and "nonspecific" agents, those producing effects on different target cells and acting by diverse molecular mechanisms. Those with nonspecific mechanisms are generally further classed according to whether they produce behavioral depression or stimulation. Those with specific mechanisms are classed by locus of action or specific therapeutic use. (From Gilman AG, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p252)
| Descriptor ID |
D002491
|
| MeSH Number(s) |
D27.505.954.427
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Central Nervous System Agents".
Below are MeSH descriptors whose meaning is more specific than "Central Nervous System Agents".
This graph shows the total number of publications written about "Central Nervous System Agents" by people in this website by year, and whether "Central Nervous System Agents" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 |
| 2002 | 2 | 1 | 3 |
| 2005 | 5 | 0 | 5 |
| 2006 | 3 | 2 | 5 |
| 2007 | 1 | 1 | 2 |
| 2008 | 1 | 2 | 3 |
| 2009 | 3 | 6 | 9 |
| 2010 | 4 | 2 | 6 |
| 2011 | 1 | 1 | 2 |
| 2012 | 3 | 1 | 4 |
| 2014 | 1 | 3 | 4 |
| 2015 | 2 | 0 | 2 |
| 2016 | 6 | 1 | 7 |
| 2017 | 5 | 4 | 9 |
| 2018 | 3 | 2 | 5 |
| 2019 | 2 | 1 | 3 |
| 2020 | 0 | 2 | 2 |
| 2021 | 2 | 0 | 2 |
| 2022 | 0 | 2 | 2 |
| 2024 | 0 | 2 | 2 |
Below are the most recent publications written about "Central Nervous System Agents" by people in Profiles.
-
Deep phenotypic profiling of neuroactive drugs in larval zebrafish. Nat Commun. 2024 Nov 17; 15(1):9955.
-
Diagnoses and Treatment of Behavioral and Psychological Symptoms of Dementia Among Racially and Ethnically Diverse Persons Living with Dementia. J Alzheimers Dis. 2024; 99(2):513-523.
-
A Mixed-methods Evaluation of an Addiction/Cardiology Pilot Clinic With Contingency Management for Patients With Stimulant-associated Cardiomyopathy. J Addict Med. 2023 May-Jun 01; 17(3):312-318.
-
Defining Steric Requirements at CB1 and CB2 Cannabinoid Receptors Using Synthetic Cannabinoid Receptor Agonists 5F-AB-PINACA, 5F-ADB-PINACA, PX-1, PX-2, NNL-1, and Their Analogues. ACS Chem Neurosci. 2022 04 20; 13(8):1281-1295.
-
Psychotropic medication prescribing during the COVID-19 pandemic. Medicine (Baltimore). 2021 Oct 29; 100(43):e27664.
-
Change in central nervous system-active medication use following fall-related injury in older adults. J Am Geriatr Soc. 2022 01; 70(1):168-177.
-
Prevalence of Central Nervous System-Active Polypharmacy Among Older Adults With Dementia in the US. JAMA. 2021 03 09; 325(10):952-961.
-
Synthesis and in Vitro Cannabinoid Receptor 1 Activity of Recently Detected Synthetic Cannabinoids 4F-MDMB-BICA, 5F-MPP-PICA, MMB-4en-PICA, CUMYL-CBMICA, ADB-BINACA, APP-BINACA, 4F-MDMB-BINACA, MDMB-4en-PINACA, A-CHMINACA, 5F-AB-P7AICA, 5F-MDMB-P7AICA, and 5F-AP7AICA. ACS Chem Neurosci. 2020 12 16; 11(24):4434-4446.
-
Polypharmacy in patients with epilepsy: A nationally representative cross-sectional study. Epilepsy Behav. 2020 10; 111:107261.
-
A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia. Nat Med. 2020 05; 26(5):760-768.